SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending, and the community is actively engaging with the classic "What's UpDog?" joke, driving social volume. Some users are pointing out the project has been live on Solana for over a year and has a locked and burned LP. Others suggest the recent increase in social volume is due to only one or two accounts.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors anticipate upcoming earnings, with community members highlighting the potential impact of QNX technology and key partnerships with companies like AMD and Nvidia. Bullish sentiment is fueled by expectations of strong financial performance and the possibility of future share buybacks. Some investors suggest BlackBerry is undervalued, drawing comparisons to AMD's earlier growth trajectory.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MLTX is trending due to positive Phase 2 trial data for its drug sonelokimab in treating hidradenitis suppurativa, leading to raised price targets and speculation about its potential as a best-in-class treatment. The community is actively discussing the implications of this data, especially compared to competitors, and the possibility of a future buyout. Some investors believe MLTX is thoroughly de-risked.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

BOB.X is trending as users discuss its potential as the next BTC.X, highlighting its capped supply and upcoming halving event. Community members are also excited about its multi-chain availability and integration within the ICP.X ecosystem.

WeRide, Inc. is a holding company, which engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers, and related sensor suites. The company was founded by Tony Xu Han and Yan Li on March 13, 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide ($WRD) is trending due to discussions around its partnerships and deployments in the Middle East and Southeast Asia, including Singapore and Abu Dhabi. The community is debating whether WeRide is undervalued compared to competitors like Pony.ai, despite its revenue growth and expansion. Recent news of UBS initiating coverage with a buy rating and the upcoming Grab earnings call are also fueling interest.

Invesco DB US Dollar Index Trust - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

The U.S. Dollar Index ($UUP) is trending as traders weigh the potential impact of a strong dollar against expectations for future Federal Reserve policy. Community members are analyzing technical indicators and potential breakout levels, while also considering the impact of tariffs and trade deals. Discussions revolve around the dollar's relationship with other asset classes like gold and equities.

ProShares Trust - ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF

VIXY is trending as traders discuss potential market volatility driven by factors like geopolitical tensions (Middle East), tariff concerns, and economic data. Community members are actively analyzing yearly charts and technical patterns, with some anticipating a volatility spike and hedging their portfolios, while others point to the potential for market manipulation.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas is trending as the community discusses its recent listing on MEXC and potential for significant growth. Comparisons to other tokens like PENGU are circulating, with many highlighting its strong fundamentals and NFT presence. Holders are expressing bullish sentiment, anticipating a potential breakout and encouraging others to research the token.

its a Meme token and beta to Troll The "Lenny face  is a text-based emoticon, ( ͡° ͜ʖ ͡°), used to convey a range of emotions, particularly mischief, sexual innuendo, or a hidden meaning. It's often employed in online discussions to add a playful or suggestive tone to a message, or sometimes even to spam threads, according to Wikipedia. The symbol is visually interpreted as a face with two eyes (small circles), a nose (squiggly line), and a mouth (curved line).

Lenny

$LENNY.X is trending as the 'OG face of the internet' aims to build a strong community and 'Lenny Cult'. Social media mentions highlight conviction and relentless grinding towards solidifying the project's place in meme history, with community members encouraging others to 'get Lennyfied'.

Marathon Petroleum Corp. engages in the refining, marketing, and transportation of petroleum products. It operates through the Refining and Marketing, and Midstream segments. The Refining and Marketing segment includes refining crude oil and other feedstocks, purchasing ethanol, and refined products for resale and distribution of refined products. The Midstream segment refers to transportation, storing, distribution, and marketing of crude oil and refined products. The company was founded in 1887 and is headquartered in Findlay, OH.

Marathon Petroleum Corp

Marathon Petroleum is trending amid unusual options activity and high trading volume, suggesting bullish sentiment among some investors. Community members are actively discussing potential ROI from call options, while recent reports highlight the company's solid financial position and potential as a 'refiner cash cow' given disruptions in global oil markets.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR...

Galmed Pharmaceuticals (GLMD) shares rose sharply on Tuesday after the company reported positive preclinical data showing that its experimental drug Aramchol enhances the effectiveness of Regorafenib in liver and colon cancer models.Following the announcement, Galmed's stock rose by 10.6%, closing at $1.46 per share.&nbsp;According to the company, Aramchol improved the anti-tumor activity of Regorafenib — a multi-kinase inhibitor approved for liver and colorectal cancers — in both in-vitro and in-vivo settings.&nbsp;The combination also activated ATM and AMPK pathways while inhibiting mTORC1 and mTORC2, mechanisms known to play roles in cancer cell survival.Aramchol was also shown to work in combination with other kinase inhibitors like Sorafenib and Lenvatinib, though Regorafenib exhibited the strongest synergistic effects.&nbsp;The dual treatment suppressed tumor growth in hepatoma models without causing toxicity to normal tissues, the company said.Retail sentiment spiked following the update.&nbsp;On Stocktwits, message volume surged 4,480% over 24 hours, with sentiment marked as ‘extremely bullish.’Some retail investors suggested the stock could double from a previous $1.31 entry level.&nbsp;<stembedurl>https://stocktwits.com/debbiekatz/message/613719065</stembedurl>Others speculated the price could climb to the $2.50–$3.00 range, reflecting confidence ahead of the next trading session.<stembedurl>https://stocktwits.com/ZCOCSTOCK/message/613738896</stembedurl>Galmed said it expects to initiate a Phase 1b trial of Aramchol in combination with Regorafenib by the fourth quarter of 2025.The oncology update comes on the heels of another strategic development.&nbsp;Last week, Galmed signed a binding term sheet with Entomus s.r.o. for the licensing of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation.&nbsp;The technology enables sublingual absorption of peptides such as GLP-1, a key target in metabolic disorders.&nbsp;A definitive agreement outlining milestones and royalty terms is expected within 90 days.Shares of Galmed have fallen 56% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

RBC said Medicaid spending was politically harder to unwind than the Journal suggested, adding that many small and rural hospitals depend on these payments to stay afloat. | Image source: Getty Images

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’

The company reported that Aramchol, its experimental liver drug, enhanced Regorafenib’s anti-tumor effects without causing toxicity in preclinical models.

Equity

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology

Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology PR Newswire TEL AVIV, Israel, Sept. 25, 2024...

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases

Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases PR Newswire...

Galmed Pharmaceuticals Reports Mid-Year Loss

Galmed Pharmaceuticals (GLMD) has released an update. Galmed Pharmaceuticals Ltd. reports a net loss of $2.394 million for the first half of 2024...

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended...

StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD)

StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD - Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the...

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD  Get Free Report) in a research note issued on Saturday. The firm set a...

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis Galmed Announces Grant of New Patent for the...

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD  Free Report) in a research report sent to investors on Thursday. The firm issued a sell rating on the...

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Ltd

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$1.40
Prev Close	$1.38
Open	$1.42
Dividend Yield	0.00%
50-Day Moving Average	$1.52
Beta	0.99
Avg. Volume	234,625.29
PE Ratio	-0.26

52-Week High	$7.50
52-Week Low	$1.15
Market Capitalization	$7.67M
EPS (Annual)	-$8.08
Price to Book	0.36
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

GLMD
Galmed Pharmaceuticals Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest GLMD News

GLMD Galmed Pharmaceuticals Ltd